Form 4: Recursion Pharma CEO Sells Shares via 10b5-1 Plan
Insider Trading Report
Recursion Pharmaceuticals CEO Christopher Gibson executed a planned sale and gift of Class A Common Stock on October 10, 2025, following a conversion of Class B shares.
Summary
- Christopher Gibson, CEO and Director of Recursion Pharmaceuticals, Inc. (RXRX), reported transactions on October 10, 2025, under a Rule 10b5-1 trading plan adopted on May 12, 2025.
- Gibson converted 120,000 shares of Class B Common Stock into Class A Common Stock.
- He subsequently sold 100,000 shares of Class A Common Stock at a price of $6.04 per share.
- Additionally, Gibson gifted 20,000 shares of Class A Common Stock.
- Following these transactions, Gibson directly holds 954,229 shares of Class A Common Stock and 5,133,034 shares of Class B Common Stock.
- Indirect holdings of Class B Common Stock include 386,000 shares via LAHWRAN-3 LLC, 388,000 shares via LAHWRAN-4 LLC, and 50,000 shares via the Gibson Family Trust, where he serves as a member/manager or Trustee.
- Gibson also holds several stock options with exercise prices ranging from $2.48 to $11.40, with various vesting schedules extending into 2035.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns about discretionary selling based on new, undisclosed information. The CEO also retains significant holdings.
Positives
- The transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled, non-discretionary sale and gift rather than an immediate reaction to market conditions.
- Christopher Gibson retains a substantial beneficial ownership in the company, including over 950,000 direct Class A shares and over 5.1 million direct Class B shares, plus significant indirect holdings and stock options, demonstrating continued alignment with shareholder interests.
Negatives
- The sale of 100,000 shares by a key executive, even if planned, could be perceived negatively by some investors as a reduction in direct equity exposure.
Risks
- Potential for negative market perception or investor sentiment due to insider selling, despite the existence of a 10b5-1 plan.
Future Outlook
This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This filing, a standard insider trading report, does not provide information for broader industry trend analysis or competitive positioning.
Related Party Transactions
- The reporting person indirectly holds Class B Common Stock through LAHWRAN-3 LLC (386,000 shares), LAHWRAN-4 LLC (388,000 shares), and the Gibson Family Trust (50,000 shares), entities where he is a member, manager, or trustee.
Stakeholder Impact
- Shareholders: May observe the reduction in direct shareholding by the CEO, though the 10b5-1 plan context provides transparency regarding the planned nature of the transaction.
Key Dates
| Date | Description |
|---|---|
| 2021-01-31 | Vesting commencement date for a stock option of 1,500,000 shares (now 282,500 remaining). |
| 2022-02-04 | Vesting commencement date for a stock option of 5,436 shares. |
| 2022-03-01 | Vesting commencement date for a stock option of 416,350 shares (now 399,002 remaining). |
| 2023-03-01 | Vesting commencement date for a stock option of 813,600 shares. |
| 2024-03-01 | Vesting commencement date for a stock option of 666,898 shares. |
| 2025-03-01 | Vesting commencement date for a stock option of 1,050,567 shares. |
| 2025-05-12 | Date Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 2025-10-10 | Date of reported transactions (conversion, sale, and gift of shares). |
| 2030-12-30 | Expiration date for a stock option with an exercise price of $2.48. |
| 2032-02-04 | Expiration date for stock options with an exercise price of $11.40. |
| 2033-02-01 | Expiration date for a stock option with an exercise price of $8.55. |
| 2034-02-09 | Expiration date for a stock option with an exercise price of $10.09. |
| 2035-02-03 | Expiration date for a stock option with an exercise price of $7.25. |
Recommendation
holdA Form 4 filing, particularly one detailing transactions under a 10b5-1 plan, typically does not provide sufficient information to warrant a strong 'buy' or 'sell' recommendation. The planned nature of the sale reduces the negative signal often associated with insider selling. Investors should consider this information in the broader context of the company's financial performance, strategic outlook, and overall market conditions, maintaining a 'hold' position based solely on this filing.
Keywords
Recursion Pharmaceuticals, RXRX, Christopher Gibson, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Class A Common Stock, Class B Common Stock, Stock Options
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.